Briacell Historical Cash Flow
| BCTX Stock | USD 0.53 0.03 5.36% |
Analysis of Briacell Therapeutics cash flow over time is an excellent tool to project Briacell Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 22.3 M or Capital Expenditures of 273.4 K as it is a great indicator of Briacell Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Briacell |
About Briacell Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Briacell balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Briacell's non-liquid assets can be easily converted into cash.
Briacell Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Briacell Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Briacell Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Briacell Therapeutics' Change In Working Capital is fairly stable compared to the past year. Begin Period Cash Flow is likely to rise to about 22.3 M in 2024, despite the fact that Change In Cash is likely to grow to (19.4 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Depreciation | 15.3K | 15.3K | 83.9K | 88.1K | Stock Based Compensation | 3.1M | 2.2M | 1.8M | 1.9M |
Briacell Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Briacell Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Briacell Therapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (124.3K) | 57.2M | (16.2M) | (19.8M) | (20.4M) | (19.4M) | |
| Free Cash Flow | (1.2M) | (7.7M) | (12.5M) | (23.7M) | (24.6M) | (23.4M) | |
| Change In Working Capital | 2.4M | (2.3M) | (391.3K) | (3.5M) | 7.1M | 7.4M | |
| Begin Period Cash Flow | 143.8K | 21.2K | 57.3M | 41.0M | 21.3M | 22.3M | |
| Other Non Cash Items | 64.7K | 1.8M | 11.7M | (1.1M) | (28.1M) | (26.7M) | |
| Total Cash From Operating Activities | (1.2M) | (7.7M) | (12.5M) | (23.7M) | (24.1M) | (22.9M) | |
| Net Income | (3.7M) | (428.3K) | (26.8M) | (20.3M) | (4.9M) | (5.2M) | |
| Total Cash From Financing Activities | 1.1M | 65.0M | (3.7M) | 4.0M | 4.4M | 6.0M | |
| End Period Cash Flow | 19.5K | 57.3M | 41.0M | 21.3M | 862.1K | 819.0K | |
| Other Cashflows From Financing Activities | 376.5K | 13.7M | 6.4M | 1.6K | (681.8K) | (647.7K) | |
| Stock Based Compensation | 1.7K | 2.0M | 3.1M | 2.2M | 1.8M | 1.9M | |
| Depreciation | 14.0K | 15.3K | 15.3K | 15.3K | 83.9K | 88.1K | |
| Change To Account Receivables | (18.1K) | 10.1K | (11.4K) | 5.3K | (732.6K) | (695.9K) | |
| Investments | (591.0K) | 1.3M | 31.0K | 0.0 | (681.8K) | (647.7K) | |
| Change To Operating Activities | 310.0K | (256.8K) | (101.0K) | (628.9K) | (566.0K) | (537.7K) | |
| Change To Netincome | (360.0K) | 88.8K | (5.1M) | 14.7M | 16.9M | 17.8M | |
| Change To Liabilities | 710.5K | 3.6M | (2.2M) | 384.3K | 345.9K | 442.7K | |
| Issuance Of Capital Stock | 1.1M | 51.6M | 21.9M | 4M | 4.4M | 4.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.